SPARC and neoplasm: In a xenograft model of human osteosarcoma with high SPARC expression, nab-paclitaxel showed a tumor inhibition rate of 98.8%, which was greater than those of doxorubicin (46.1%) or paclitaxel (40.8%) [24].